DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
OLODANRIGAN
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies; Neuralgia, Postherpetic
Angiotensin II type 2 (AT-2) receptor antagonist
OLODANRIGAN
×
Maximum Phase:
2
First Approval:
None
UNII:
P0FN522VTO
Molecule Type:
Small molecule
Molecular Formula:
C32H29NO5
Molecular Weight:
507.59
AlogP:
5.44
PSA:
76.07
HBD:
1.0
HBA:
#RotB:
8.0
Source:
SRX246
2
Small molecule
Investigational
Unknown
Unknown
Anxiety; Huntington Disease; Mood Disorders; Stress Disorders, Post-Traumatic
Vasopressin V1a receptor antagonist
SRX246
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C43H48F3N5O5
Molecular Weight:
771.88
AlogP:
6.6
PSA:
102.5
HBD:
1.0
HBA:
#RotB:
11.0
Source:
TETRAHYDROCANNABIVARIN
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
TETRAHYDROCANNABIVARIN
×
Maximum Phase:
2
First Approval:
None
UNII:
I5YE3I47D8
Molecule Type:
Small molecule
Molecular Formula:
C19H26O2
Molecular Weight:
286.42
AlogP:
4.96
PSA:
29.46
HBD:
1.0
HBA:
#RotB:
2.0
Source:
MB07811
2
Small molecule
Investigational
Unknown
Unknown
Hypercholesterolemia; Hyperlipidemias; Non-alcoholic Fatty Liver Disease
Thyroid hormone receptor beta-1 agonist
MB07811
×
Maximum Phase:
2
First Approval:
None
UNII:
3Z11398FNQ
Molecule Type:
Small molecule
Molecular Formula:
C28H32ClO5P
Molecular Weight:
514.99
AlogP:
8.08
PSA:
64.99
HBD:
1.0
HBA:
#RotB:
7.0
Source:
CANNABIDIOL ACID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CANNABIDIOL ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
FJX8O3OJCD
Molecule Type:
Small molecule
Molecular Formula:
C22H30O4
Molecular Weight:
358.48
AlogP:
5.54
PSA:
77.76
HBD:
3.0
HBA:
#RotB:
7.0
Source:
DAROTROPIUM BROMIDE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Muscarinic acetylcholine receptor antagonist
DAROTROPIUM BROMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
2W2V1U785A
Molecule Type:
Small molecule
Molecular Formula:
C24H29BrN2
Molecular Weight:
425.41
AlogP:
4.9
PSA:
23.79
HBD:
0.0
HBA:
#RotB:
4.0
Source:
EPALRESTAT
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Charcot-Marie-Tooth Disease
Aldose reductase inhibitor
EPALRESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
424DV0807X
Molecule Type:
Small molecule
Molecular Formula:
C15H13NO3S2
Molecular Weight:
319.41
AlogP:
2.92
PSA:
57.61
HBD:
1.0
HBA:
#RotB:
4.0
Source:
GUSPERIMUS
2
Small molecule
Investigational
Unknown
Unknown
Granulomatosis with Polyangiitis; Immune System Diseases
Unknown
GUSPERIMUS
×
Maximum Phase:
2
First Approval:
None
UNII:
UJ0ZJ76DO9
Molecule Type:
Small molecule
Molecular Formula:
C17H37N7O3
Molecular Weight:
387.53
AlogP:
-1.31
PSA:
178.38
HBD:
8.0
HBA:
#RotB:
17.0
Source:
ENOXOLONE
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major; Mineralocorticoid Excess Syndrome, Apparent; Skin Ulcer
Unknown
ENOXOLONE
×
Maximum Phase:
2
First Approval:
None
UNII:
P540XA09DR
Molecule Type:
Small molecule
Molecular Formula:
C30H46O4
Molecular Weight:
470.69
AlogP:
6.41
PSA:
74.6
HBD:
2.0
HBA:
#RotB:
1.0
Source:
COSITECAN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
COSITECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
24R60NVC41
Molecule Type:
Small molecule
Molecular Formula:
C25H28N2O4Si
Molecular Weight:
448.6
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
DINALBUPHINE SEBACATE
2
Small molecule
Investigational
Unknown
Unknown
Pain
Unknown
DINALBUPHINE SEBACATE
×
Maximum Phase:
2
First Approval:
None
UNII:
464OXX39Y6
Molecule Type:
Small molecule
Molecular Formula:
C52H68N2O10
Molecular Weight:
881.12
AlogP:
5.95
PSA:
158.46
HBD:
4.0
HBA:
#RotB:
15.0
Source:
ND0801
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity
Neuronal acetylcholine receptor protein alpha-7 subunit agonist
ND0801
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLESATINIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Hepatocyte growth factor receptor inhibitor
GLESATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
7Q29OXD98N
Molecule Type:
Small molecule
Molecular Formula:
C31H27F2N5O3S2
Molecular Weight:
619.72
AlogP:
6.22
PSA:
97.4
HBD:
3.0
HBA:
#RotB:
11.0
Source:
MILVETEROL
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Beta-2 adrenergic receptor agonist
MILVETEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
LGY1VQ9622
Molecule Type:
Small molecule
Molecular Formula:
C25H29N3O4
Molecular Weight:
435.52
AlogP:
2.97
PSA:
113.85
HBD:
6.0
HBA:
#RotB:
12.0
Source:
EMICERFONT
2
Small molecule
Investigational
Unknown
Unknown
Irritable Bowel Syndrome; Phobia, Social
Corticotropin releasing factor receptor 1 antagonist
EMICERFONT
×
Maximum Phase:
2
First Approval:
None
UNII:
OJ8EG4264P
Molecule Type:
Small molecule
Molecular Formula:
C22H24N6O2
Molecular Weight:
404.47
AlogP:
3.12
PSA:
75.52
HBD:
1.0
HBA:
#RotB:
4.0
Source:
SODIUM NITRATE
2
Small molecule
Investigational
Unknown
Unknown
Cardiomyopathy, Hypertrophic; Ischemia; Angina, Stable; Asthma; Coronary Disease; Muscular Dystrophy, Duchenne
Unknown
SODIUM NITRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
8M4L3H2ZVZ
Molecule Type:
Small molecule
Molecular Formula:
NNaO3
Molecular Weight:
84.99
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GSK2269557
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GSK2269557
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ISUZINAXIB HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Acute Kidney Injury; Severe Acute Respiratory Syndrome
Unknown
ISUZINAXIB HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
Q99G5ZE5U5
Molecule Type:
Small molecule
Molecular Formula:
C17H18ClN3O
Molecular Weight:
315.8
AlogP:
3.59
PSA:
50.94
HBD:
1.0
HBA:
#RotB:
4.0
Source:
ZATOLMILAST
2
Small molecule
Investigational
Unknown
Unknown
Neurocognitive Disorders; Alzheimer Disease; Fragile X Syndrome
Phosphodiesterase 4D inhibitor
ZATOLMILAST
×
Maximum Phase:
2
First Approval:
None
UNII:
G786V328X6
Molecule Type:
Small molecule
Molecular Formula:
C21H15ClF3NO2
Molecular Weight:
405.8
AlogP:
5.64
PSA:
50.19
HBD:
1.0
HBA:
#RotB:
5.0
Source:
LANICEMINE
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder; Depressive Disorder, Major
Glutamate [NMDA] receptor blocker
LANICEMINE
×
Maximum Phase:
2
First Approval:
None
UNII:
9TMU325RK3
Molecule Type:
Small molecule
Molecular Formula:
C13H14N2
Molecular Weight:
198.27
AlogP:
2.32
PSA:
38.91
HBD:
1.0
HBA:
#RotB:
3.0
Source:
HT-0712
2
Small molecule
Investigational
Unknown
Unknown
Memory Disorders; Rhinitis, Allergic, Seasonal
Phosphodiesterase 4 inhibitor
HT-0712
×
Maximum Phase:
2
First Approval:
None
UNII:
2O43FXG9IG
Molecule Type:
Small molecule
Molecular Formula:
C25H31NO3
Molecular Weight:
393.53
AlogP:
4.79
PSA:
47.56
HBD:
1.0
HBA:
#RotB:
6.0
Source:
OBI-3424
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Biphenotypic, Acute
DNA cross-linking agent
OBI-3424
×
Maximum Phase:
2
First Approval:
None
UNII:
X6SH5T8H76
Molecule Type:
Small molecule
Molecular Formula:
C21H25N4O6P
Molecular Weight:
460.43
AlogP:
3.91
PSA:
105.0
HBD:
0.0
HBA:
#RotB:
9.0
Source:
RADAFAXINE
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major
Unknown
RADAFAXINE
×
Maximum Phase:
2
First Approval:
None
UNII:
Q47741214K
Molecule Type:
Small molecule
Molecular Formula:
C13H18ClNO2
Molecular Weight:
255.74
AlogP:
2.27
PSA:
41.49
HBD:
2.0
HBA:
#RotB:
1.0
Source:
PIDOLIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PIDOLIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
SZB83O1W42
Molecule Type:
Small molecule
Molecular Formula:
C5H7NO3
Molecular Weight:
129.12
AlogP:
-0.65
PSA:
66.4
HBD:
2.0
HBA:
#RotB:
1.0
Source:
SRT-2104
2
Small molecule
Investigational
Unknown
Unknown
Colitis, Ulcerative; Muscular Atrophy; Pulmonary Disease, Chronic Obstructive; Sepsis; Diabetes Mellitus, Type 2; Psoriasis
NAD-dependent deacetylase sirtuin 1 activator
SRT-2104
×
Maximum Phase:
2
First Approval:
None
UNII:
4521NR0J09
Molecule Type:
Small molecule
Molecular Formula:
C26H24N6O2S2
Molecular Weight:
516.65
AlogP:
4.97
PSA:
84.65
HBD:
1.0
HBA:
#RotB:
6.0
Source:
BUDIODARONE
2
Small molecule
Investigational
Unknown
Unknown
Atrial Fibrillation
Unknown
BUDIODARONE
×
Maximum Phase:
2
First Approval:
None
UNII:
F5Y53150C8
Molecule Type:
Small molecule
Molecular Formula:
C27H31I2NO5
Molecular Weight:
703.35
AlogP:
6.48
PSA:
68.98
HBD:
0.0
HBA:
#RotB:
12.0
Source:
13-DEOXYDOXORUBICIN
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Unknown
13-DEOXYDOXORUBICIN
×
Maximum Phase:
2
First Approval:
None
UNII:
1S9VO1DQG5
Molecule Type:
Small molecule
Molecular Formula:
C27H31NO10
Molecular Weight:
529.54
AlogP:
0.82
PSA:
189.0
HBD:
6.0
HBA:
#RotB:
5.0
Source:
OROTIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
OROTIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
61H4T033E5
Molecule Type:
Small molecule
Molecular Formula:
C5H4N2O4
Molecular Weight:
156.1
AlogP:
-1.24
PSA:
103.02
HBD:
3.0
HBA:
#RotB:
1.0
Source:
DEXPRAMIPEXOLE DIHYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis; Asthma
Unknown
DEXPRAMIPEXOLE DIHYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
795J01AE70
Molecule Type:
Small molecule
Molecular Formula:
C10H21Cl2N3OS
Molecular Weight:
302.27
AlogP:
1.58
PSA:
50.94
HBD:
2.0
HBA:
#RotB:
3.0
Source:
BMS-813160
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Pancreatic Ductal; Hyperplasia; Diabetic Nephropathies; Neoplasms
C-C chemokine receptor type 2 antagonist
BMS-813160
×
Maximum Phase:
2
First Approval:
None
UNII:
83U7957287
Molecule Type:
Small molecule
Molecular Formula:
C25H40N8O2
Molecular Weight:
484.65
AlogP:
2.25
PSA:
116.55
HBD:
3.0
HBA:
#RotB:
5.0
Source:
DEOXYCYTIDINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DEOXYCYTIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
0W860991D6
Molecule Type:
Small molecule
Molecular Formula:
C9H13N3O4
Molecular Weight:
227.22
AlogP:
-1.53
PSA:
110.6
HBD:
3.0
HBA:
#RotB:
2.0
Source:
GSK2798745
2
Small molecule
Investigational
Unknown
Unknown
Cough; Macular Edema; Heart Failure; Pulmonary Edema
Transient receptor potential cation channel subfamily V member 4 antagonist
GSK2798745
×
Maximum Phase:
2
First Approval:
None
UNII:
63FJ7LF55O
Molecule Type:
Small molecule
Molecular Formula:
C25H28N6O3
Molecular Weight:
460.54
AlogP:
3.9
PSA:
117.16
HBD:
1.0
HBA:
#RotB:
4.0
Source:
AFP-464
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms
Unknown
AFP-464
×
Maximum Phase:
2
First Approval:
None
UNII:
73JNH95XPX
Molecule Type:
Small molecule
Molecular Formula:
C26H35F3N4O9S2
Molecular Weight:
668.71
AlogP:
3.94
PSA:
137.37
HBD:
4.0
HBA:
#RotB:
9.0
Source:
TANSHINONE IIA SULFONATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
TANSHINONE IIA SULFONATE
×
Maximum Phase:
2
First Approval:
None
UNII:
5CKR8JG9OW
Molecule Type:
Small molecule
Molecular Formula:
C19H17NaO6S
Molecular Weight:
396.4
AlogP:
3.49
PSA:
101.65
HBD:
1.0
HBA:
#RotB:
1.0
Source:
Q203
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
Q203
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
116
117
118
119
120
121
122
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA